Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum

NCT00056030 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00056030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2004
Completion date
Not reported
Enrollment
73 (estimated)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic cancer